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Abstract
Introduction: The aim of the present study was to evaluate the effect of modest weight reduction on serum concentrations of tumour necrosis
factor a (TNF-a), TNF soluble receptors (sTNFRs) and interleukin-6 (IL-6) in obese women with polycystic ovary syndrome (PCOS).
Material and methods: The study group consisted of 15 obese women with PCOS (mean age 28.5 ± 7.7 years). Serum concentrations of
TNF-a, sTNFRs and IL-6, insulin, FSH, LH, DHEAS, androstendione, total and free testosterone, cortisol, 17OH-progesterone, oestradiol
and sex hormone binding globulin (SHBG), glucose, total cholesterol, HDL cholesterol and triglycerides were measured before treatment
and after 10% weight loss.
All patients were advised to follow a 1000–1200 kcal diet with a limited intake of simple carbohydrate and animal fats and to exercise
regularly (30 min, 3 times a week).
Body composition was measured by bioimpedance. Serum concentrations of TNF-a, sTNFRs and IL-6 were determined by enzyme linked
immunosorbent assay (ELISA). Plasma insulin, FSH, LH, DHEAS, androstendione, total and free testosterone, cortisol, 17OH-progesterone,
oestradiol and SHBG were measured by a commercial RIA. Blood glucose, total cholesterol, HDL cholesterol and triglycerides were me-
asured by an enzymatic procedure.
Results: We observed no differences in serum concentrations of TNF-a, sTNFRs or IL-6 after treatment.
Conclusions: It seems that more than a modest weight reduction is necessary to obtain a decrease in serum concentrations of proinflam-
matory cytokines and an improvement in ovarian function in obese women with polycystic ovary syndrome.
(Pol J Endocrinol 2008; 59 (1): 13–17)
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Streszczenie
Wstęp: Celem prezentowanej pracy była ocena wpływu umiarkowanej redukcji masy ciała na stężenia czynnika martwicy nowotworu a
(TNF-a, tumour necrosis factor a) rozpuszczalnych receptorów dla TNF w osoczu otyłych kobiet z zespołem policystycznych jajników.
Materiał i metody: Piętnaście otyłych kobiet (średnia wieku 28,5 ± 7,7 roku) z zespołem policystycznych jajników poddano kuracji
odchudzającej składającej się z diety 1000 kcal oraz aktywności fizycznej. Oceniano stężenie czynnika martwicy nowotworów, rozpusz-
czalnych receptorów dla TNF oraz IL-6, insuliny, FSH, LH, DHEAS, androstendionu, całkowitego oraz wolnego testosteronu, kortyzolu,
17OH-progesteronu, estradiolu, SHBG, glukozy, cholesterolu całkowitego, cholesterolu frakcji HDL oraz triglicerydów przed rozpoczę-
ciem kuracji odchudzającej oraz po 10-procentowym zmniejszeniu masy ciała. Pacjentkom zalecono przestrzeganie diety 1000–1200 kcal
z ograniczeniem spożycia węglowodanów prostych oraz tłuszczów zwierzęcych oraz regularną aktywność fizyczną (co najmniej 30 min,
3 razy w tygodniu).
Skład ciała oznaczono przy użyciu metody bioimpedancji. Stężenia TNF-a, receptorów dla TNF oraz IL-6 w surowicy oznaczono metodą
ELISA. Stężenie insuliny, FSH, LH, DHEAS, androstendionu, całkowitego i wolnego testosteronu, kortyzolu, 17OH-progesteronu, estra-
diolu oraz SHBG oznaczono przy użyciu metody RIA. Stężenia glukozy, cholesterolu całkowitego, cholesterolu frakcji HDL oraz triglice-
rydów oznaczono metodą enzymatyczną.
Wyniki: Nie zaobserwowano różnic w stężeniu TNF-a, rozpuszczalnych receptorów dla TNFR oraz IL-6 przed rozpoczęciem kuracji oraz
po redukcji masy ciała.
Wnioski: Wydaje się, że umiarkowana redukcja masy ciała jest niewystarczająca do uzyskania zmniejszenia stężeń cytokin prozapalnych
u otyłych kobiet z zespołem policystycznych jajników oraz do poprawy czynności jajników. (Endokrynol Pol 2008; 59 (1): 13–17)
Słowa kluczowe: cytokiny prozapalne, redukcja masy ciała, zespół policystycznych jajników
14
Inflammation in PCOS Magdalena Olszanecka- Glinianowicz et al.
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Introduction
Obesity is a very common clinical feature in women
affected by polycystic ovary syndrome (PCOS); appro-
ximately 50% of PCOS women are obese and their hi-
story of weight gain frequently precedes the onset of
oligomenorrhea and hyperandrogenism [1].
It is well-known that hyperinsulinaemia and insu-
lin resistance play an important part in the pathogene-
sis of PCOS [2]. It has been shown in a number of stu-
dies that the adipose tissue alone generates many sub-
stances which may participate in the development of
insulin resistance, including free fatty acids, tumour
necrosis factor a (TNF-a), interleukin-6 (IL-6), leptin and
resistin [3].
Our previous studies have revealed increased serum
concentrations of proinflammatory cytokines such as
TNF-a and IL-6 in obese subjects without additional
disease [4, 5, 6]. However, we observed no difference
between PCOS and obese women without additional
disease in plasma TNF-a concentrations, but plasma
concentrations of both TNF soluble receptors (sTNFRs)
sTNFR1 and sTNFR2 were significantly increased and
serum IL-6 concentrations were significantly decreased
in women without additional diseases and in women
with PCOS [7].
So far few studies have been carried out to evaluate
the effect of weight loss on serum concentrations of
TNF-a, sTNFRs and IL-6. In those that have been publi-
shed a decrease in serum concentrations of TNF-a and
IL-6 and an increase in serum concentrations of sTNFR1
and sTNFR2 were observed after weight loss [4–6].
Recent studies have revealed an improvement in
ovarian function after weight reduction in obese wo-
men with PCOS [8, 9]. However, no studies have been
conducted to investigate the influence of weight loss
treatment on changes in TNF system activity and se-
rum concentrations of IL-6 in obese women with PCOS.
The aims of the present study, therefore, were to evalu-
ate the effect of modest weight loss on serum concen-
trations of TNF-a, sTNFRs and IL-6 and to examine
whether there is any association between these cytoki-
nes, changes in their concentrations and serum concen-
trations of androgens after weight loss.
Materials and methods
The study group consisted of 15 obese women with
PCOS (aged 28.5 ± 7.7 years). The diagnosis of PCOS
was based on both clinical symptoms, primarily oligo-
menorrhea and hirsutism, and laboratory findings, inc-
luding serum androgen levels (DHEAS, androstendio-
ne, testosterone, and free testosterone) which were abo-
ve the upper limit of the norm for the respective assay.
The patients were included in the study directly after
hormonal and ultrasonographic diagnosis of PCOS.
In all the subjects included in the study Cushing’s syn-
drome, thyroid dysfunction, androgen-secreting tumour
and enzyme deficiency (of 21-hydroxylase in particular)
were excluded. All patients were free of other diseases and
were not undergoing pharmacological treatment. Other
exclusion criteria included evidence of present or recent
(during the preceding three months) infectious disease,
fever, smoking or drug therapy. The characteristics of the
study group are summarised in Table I.
The women underwent weight loss treatment. They
were advised to follow a 1000–1200 kcal diet with a li-
mited intake of simple carbohydrate and animal fats and
to exercise regularly (30 min, 3 times a week). Pharma-
cological treatment was not administered.
The study was only conducted after informed con-
sent had been obtained from all the subjects. The study
was approved by the local committee for ethics.
Before and after treatment body weight and height
were measured and body mass index (BMI) was calcu-
lated as weight in kilograms divided by the square of
the height in metres. Body composition was determi-
ned by impedance analysis using a Bodystat analyser.
All the women were studied within 10 days of the
onset of menstruation. Blood samples were taken in the
morning subsequent to an overnight fast. The samples
were centrifuged (1000 g) at room temperature for
10 minutes. The serum obtained was drawn into plastic
vials, and stored at –80°C until the time of the assay.
Assays
Blood glucose, total cholesterol, HDL cholesterol and
triglycerides were measured by an enzymatic procedure
(Diagnostic Products Corporation USA). LDL cholesterol
was calculated with the Friedewald formula. Plasma in-
sulin was measured by a commercial RIA (Diagnostic Pro-
Table I. Patient characteristics and the effect of weight-
reducing treatment
Tabela I. Charakterystyka pacjentów i efekty kuracji
odchudzającej
n = 15 Before After
Weight (kg) 96.6±17.0  84.7±14.5 ***
BMI [kg/m2]  36.1±6.6  31.6±5.8 ***
Fat-free mass (kg)  53.8±8.1  49.1±4.7 *
Fat-free mass (%)  56.4±6.7  58.9±6.4
Body fat (kg)  42.6±12.5  35.5±11.2 ***
Body fat (%)  43.5±6.7  41.1±6.4
* — p < 0.01; *** — p < 0.00001
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ducts Corporation, USA) with a lower limit of sensitivity
of 1.2 mIU/ml and intra-assay and inter-assay coefficients
of variations of 5.2% and 5.8% respectively.
Insulin resistance was assessed on the basis of fa-
sting serum concentrations of glucose and insulin, the
HOMA index being calculated by the formula HOMA
= fasting serum concentration of insulin (mIU/ml) ×
× fasting serum concentration of glucose (mmol/l)/22.5.
The normal range according to HOMA is < 2.77.
Serum FSH and LH were determined by RIA (Orion
Diagnostics, Finland) with a lower limit of sensitivity of
0.1 IU/l and 0.07 IU/l respectively. The respective intra-
assay and inter-assay coefficients of variation were
2.0 and 4.2 for FSH and 2.6 and 4.4 for LH.
DHEAS, androstendione, free testosterone, cortisol,
17OH-progesterone and sex hormone binding globu-
lin (SHBG) were assayed by RIA (Diagnostic Products
Corporation, USA) with lower detectable concentrations
of 0.03 mmol/l; 0.1 nmol/l; 0.5 pmol/l; 5.5 nmol/l;
0.2 nmol/l; 3 nmol/l respectively.
The respective inter-assay and intra-assay coeffi-
cients of variation were 4.7% and 8.3% for DHEAS,
4.2% and 7.6% for androstendione, 11.6% and 11.6%
for free testosterone, 4.3% and 5.2% for cortisol, 5.6%
and 8.0% for 17OH-progesterone and 2.7% and 10.2%
for SHBG.
Oestradiol (E2), total testosterone, and progestero-
ne were determine by RIA (Orion Diagnostics, Finland)
with a lower sensitivity of 20.0 pmol/l, 0.1 nmol/l and
£ 0.3 nmol/l respectively. The respective inter-assay and
intra-assay coefficients of variation were 5.8% and 6.5%
for E2, 5.3% and 5.4% for total testosterone and 4.3%
and 5.0% for progesterone.
Of the proinflammatory cytokines, TNF-a, sTNFR1
and sTNFR2 and IL-6 were determined by enzyme lin-
ked immunosorbent assay (ELISA) (Genzyme Diagno-
stics, Cambridge, USA, R&D Systems); IL-6 was also as-
sayed by ELISA (Diagnostic Products Corporation, USA).
The minimum detectable dose of TNF-a is typically
less than 0.18 pg/ml. The mean intra-assay coefficient
of variance was 14.4%, range 8.7–14.8%, and the mean
inter-assay coefficient of variance was 18.7%, range 16.1–
–22.6%. The minimum detectable dose of sTNFR1 is ty-
pically less than 3.0 pg/ml. The mean intra-assay coeffi-
cient of variance was 2.9%, range 2.7–6.9% and the mean
inter-assay coefficient of variance was 3.7%, range 5.8–
–8.8%. The minimum detectable dose of sTNFR2 is ty-
pically less than 1.0 pg/ml. The mean intra-assay coeffi-
cient of variance was 2.5%, range 1.6–2.5% and the mean
inter-assay coefficient of variance was 3.5%, range 3.5–
–5.1%. The minimum detectable dose of IL-6 is typical-
ly less than 1.0 pg/ml. The mean intra-assay coefficient
of variance was 10% and the mean inter-assay coeffi-
cient of variance was < 10%.
Statistics
Statistical analyses were performed with STATISTICA
software. All text and table values were expressed as
means ± SD. P values less than 0.05 were considered to
be statistically significant. The non-parametric Mann
Whitney U test was used to analyse differences betwe-
en the study group and controls. Spearman’s correla-
tion coefficients were used to test the correlation be-
tween variables. We used the Bonferroni correction for
the multiple comparisons when four serum markers
were tested in the same set of patients.
Results
The mean weight loss during treatment was 11.9 ± 4.5 kg
(12.2 ± 3.6%). The effect of the weight loss treatment is
presented in Table I.
There were no differences between serum concen-
trations of insulin, glucose, HOMA index and lipids
before and after treatment. These data are shown in
Table II.
 No significant changes of serum FSH, LH, LH/FSH
ratio, total and free testosterone, androstendione and
17OH-progesterone were observed after weight loss
(Table III), nor did we observe differences in concen-
trations of plasma TNF-a, sTNFRs sTNFR1 and sTNFR2
or IL-6 after weight reduction (Table IV).
Correlations between the anthropometric parameters
and the remaining parameters before treatment
We observed significant positive linear correlations
between serum concentration of IL-6 and body mass
(r = 0.55; p < 0.05), BMI (r = 0.63; p < 0.05), body fat in
kilograms (r = 0.67; p < 0.01) and body fat percentage
(r = 0.77; p < 0.005).
Significant positive linear correlations were also
shown between serum concentrations of sTNFR1 and
Table II. Plasma lipids, glucose, insulin and HOMA
Tabela II. Stężenia lipidów, glukozy i insuliny w osoczu oraz
wskaźnik HOMA
Before After weight loss
Total cholesterol [mmol/l] 5.2±1.0 4.9±0.7
HDL cholesterol [mmol/l] 1.3±0.3 1.2±0.3
LDL cholesterol [mmol/l] 3.4±1.1 3.2±0.7
Triglycerides [mmol/l] 1.4±0.7  1.1±0.4*
Glucose [mmol/l] 5.3±0.7 5.1±0.7
Insulin [mIU/ml]  13.4±8.6  17.1±8.7
HOMA 3.3±2.5 4.0±2.1
* — p < 0.05
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body mass (r = 0.58; p < 0.05), BMI (r = 0.58; p < 0.05)
and body fat in kilograms (r = 0.62; p < 0.02).
We also observed a negative linear correlation be-
tween serum concentrations of DHEAS and body mass
(r = –0.53; p < 0.05).
Correlations between anthropometric parameters
and the remaining parameters after treatment
Significant positive linear correlations wee shown
between serum concentrations of TNF-a and body mass
(r = 0.58; p < 0.05) and between serum concentrations
of insulin and body mass (r = 0.58; p < 0.05) and BMI
(r = 0.54; p < 0.05).
Correlations between serum cytokines levels
and the remaining parameters before treatment
A positive linear correlation was found between se-
rum TNF-a and TNFR2 (r = 0.60; p < 0.05).
Correlations between serum cytokine levels
and the remaining parameters after treatment
Positive linear correlations were found between con-
centrations of serum TNFR1 and LH (r = 0.66; p = 0.01)
and between serum IL-6 and estuarial concentrations
(r = 0.64; p = 0.04).
Discussion
Some recent studies have revealed that in obese wo-
men with PCOS weight loss improves insulin sensitivi-
ty, decreases serum concentrations of androgens and
increases serum concentration of SHBG [8, 10]. In the
present study in 15 obese subjects with PCOS we obta-
ined a mean weight reduction of 12.2 ± 3.6%. Howe-
ver, favourable changes in hormonal parameters were
not observed. This agrees with the results obtained by
Moran et al. [11], which showed that only 44% of obese
subjects with PCOS saw an improvement in the regu-
larity of periods after weight reduction. However, Di-
xon and O’Brien [12] reported an increase in SHBG and
a decrease in testosterone only one year after gastric
by-pass and a weight reduction of 43%. On the basis of
these results it seems that more than modest weight
reduction is necessary to obtain an improvement in the
hormonal profile of obese women with PCOS.
Our recent results and those of other authors [7, 13]
have revealed that PCOS is not per se associated with
increased chronic inflammation. However, as pointed
out above, there have so far been no studies concer-
ning the influence of weight loss treatment on inflam-
mation in obese women with PCOS.
An interesting and novel finding of the present study
is that, in contrast to the results described above [4–6],
we did not observe changes in serum concentrations of
TNF-a after weight reduction. Therefore it seems that
in obese women with PCOS adipose tissue is not the
most important source of TNF-a and that there are other
mechanisms regulating serum concentrations of TNF-a
in this disease. Winkler et al. [14] revealed expression
of the TNF-a protein in both subcutaneous and visce-
ral fat deposits and a correlation of serum TNF-a with
adipocyte cell volume in obese subjects without addi-
tional disease.
Our recent study revealed increased serum concen-
trations of sTNFRs in obese women with PCOS when
compared to obese women with no additional disease [7].
Previously we had also observed significantly increased
serum concentrations of sTNFRs after weight loss [4].
However, the present study did not reveal changes in
serum concentrations of sTNFR1 and sTNFR2 after
weight loss in PCOS women. This may be one of the
causes of the lack of decrease in serum concentrations
of TNF-a. Besides blocking TNF binding by cell surface
receptors, sTNFRs may stabilise and even enhance the
effects of TNF-a by slowing down the dissociation rate
from a trimeric to an inactive monomeric structure. The
second property of soluble receptors makes it possible
that they serve as a reservoir of bio-active TNF which
prolongs the TNF-a activity [15]. However, further stu-
dies are required to establish the causes of the lack of
Table IV. Serum concentrations of TNF-a, TNF receptors and IL-6
Tabela IV. Stężenie TNF-a, receptorów TNF i IL-6 w surowicy
Before After
TNF-a [pg/ml] 6.6±3.0  6.1±3.6
sTNFR1 [pg/ml] 2209.7±979.7 2043.7±631.4
sTNFR2 [pg/ml] 2415.7±692.8 2001.8±793.2
IL-6 [pg/ml] 6.0±2.0 4.7±2.1
Table III. Serum concentrations of hormones
Tabela III. Stężenia hormonów w surowicy
Before After
FSH [IU/l]  6.3±2.3  5.8±2.8
LH [IU/l]  7.7±5.8  9.3±7.6
DHEAS [mg/dl] 525.7±168.1 244. 3±125.4
Androstendione [ng/ml] 4.6±2.0 5.4±2.4
Total testosterone [nmol/l] 2.4±0.9 2.0±0.8
Free testosterone [pg/ml] 4.1±2.2 4.0±2.1
Cortisol [mg/dl] 19.5±10.4 17.9±7.7
Oestradiol [pmol/l] 330.5±320.2 452.6±482.1
17OH-progesterone [ng/ml] 2.2±1.8 2.0±1.3
SHBG [nmol/l] 30.2±17.1 33.2±17.1
17
Endokrynologia Polska/Polish Journal of Endocrinology 2008; 59 (1)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
change in serum concentrations of sTNFRs after we-
ight reduction.
In the present paper serum concentration of IL-6
decreased, albeit not significantly, after weight loss. It
therefore seems that this cytokine is most dependent
on fat deposits in PCOS too. This is in accordance with
the results of our earlier study [6] and with the correla-
tions observed in the present study, namely the signifi-
cant positive linear correlations between serum concen-
tration of IL-6 and body mass, BMI, body fat in kilo-
grams and body fat percentage.
In summary, this is a preliminary study to examine
the effect of weight reduction on serum TNF system ac-
tivity and serum concentrations of IL-6. Moreover, the
results obtained differ from those of studies involving
women with simple obesity but without additional dise-
ase. Further studies are therefore necessary to clarify the
role of proinflammatory cytokines in PCOS and the me-
chanisms regulating their serum concentrations.
Conclusions
It seems that more than a modest weight reduction is ne-
cessary to obtain a decrease in serum concentrations of pro-
inflammatory cytokines and an improvement in ovarian
function in obese women with polycystic ovary syndrome.
References
1. Gambineri A, Pelusi C, Vicennati V et al. Obesity and the polycystic ova-
ry syndrome. Intern J Obes Relat Metab Disord 2002; 26: 883–896.
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: me-
chanism and implications for pathogenesis. Endocrinol Rev 1997; 18:
774–800.
3. Frühbeck G, Gomez-Ambrosi J, Muruzàbal FJ et al. The adipocyte:
a model for integration of endocrine and metabolic signaling in ener-
gy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280:
827–847.
4. Zahorska-Markiewicz B, Janowska J, Olszanecka-Glinianowicz M et al.
Serum concentrations of TNF-a and soluble TNF-a receptors in obesity.
Intern J Obes Relat Metab Disord 2000; 24: 1392–1395.
 5. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Janowska J et al.
Serum concentrations of nitric oxide, TNF-a and TNF soluble recep-
tors in women with overweight and obesity. Metabolism 2004; 53:
1268–1273.
 6. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Kocełak P et al. The
effect of weight loss on serum concentration of interleukin-6 (IL-6) and
insulin resistance. Pol J Endocrinol 2006; 57: 131–135.
 7. Olszanecka-Glinianowicz M, Banaś M, Zahorska-Markiewicz B et al. Is
the polycystic ovary syndrome associated per se with chronic inflamma-
tion? Eur J Obstet Gynecol Reprod Biol 2007; 13: 197–202.
 8. Guzick DS, Wing R, Smith D et al. Endocrine consequences of weight
loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994;
61: 598–604.
 9. Kiddy DS, Hamilton-Fairley D, Bush A et al. Improvement in endocrine
and ovarian function during dietary treatment without dietary restric-
tion. Int J Obes 1999; 23: 1016–1024.
10. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Jochemczyk-
-Banek U et al. Sibutramin administration in polycystic ovary syndrome
treatment. Gynecol Pol 2004; 75: 470––474.
11. Moran LJ, Noakes M, Clifton PM et al. Dietary composition in restoring
reproductive and metabolic physiology in overweight women with po-
lycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 812–819.
12. Dixon BJ, O’Brien PE. Neck circumference a good predictor of raised in-
sulin and free androgen index in obese premenopausal women: changes
with weight loss. Clin Endocrinol 2002; 57: 769–778.
13. Möhlig M, Spranger J, Osterhoff M et al. The polycystic ovary syndrome
per se is not associated with increased chronic inflammation. Europ
J Endocrinol 2004; 150: 525–532.
14. Winkler G, Kiss S, Kesztheleyi L et al. Expression of tumor necrosis factor
(TNF)-a protein in the subcutaneous and visceral adipose tissue in corre-
lation with adipocyte cell volume, serum TNF-a, soluble serum TNF-re-
ceptor-2 concentrations and C-peptide level. Eur J Endocrinol 2003; 149:
129–135.
15. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G et al. Soluble recep-
tors for tumour necrosis factor in clinical laboratory diagnosis. Eur J He-
matol 1995; 54: 1–8.
